EvansMDS

A funding initative of the Edward P. Evans Foundation

EDWARD P. EVANS FOUNDATIONCONTACT
  • ABOUT MDS
    • ABOUT MDS
    • RESOURCES
    • EDWARD P. EVANS
  • FUNDING MDS RESEARCH
    • FUNDING MDS RESEARCH
    • RESEARCHER PROFILES
    • FUNDING INFORMATION
    • CENTERS FOR MDS
  • EVANS MDS SUMMIT
  • LEADERSHIP
  • CONTACT
  • EDWARD P. EVANS FOUNDATION

Kielkopf, Clara, Ph.D. 2016

Researcher Profiles

Researcher Profiles

<BACK TO ALL RESEARCHERS

Clara Kielkopf, Ph.D.

Clara Kielkopf, Ph.D.

University of Rochester

2016 Grant Recipient

Structural mechanisms and targeting of MDS-relevant pre-mRNA splicing factors

Discovery Research Grant 2016

PROJECT SUMMARY

Patients with myelodysplastic syndromes (MDS) acquire defects in the molecular machinery for “splicing” gene transcripts into legible RNA messages. Normally, these so-called “splicing factors” process gene transcripts into legible RNA messages. We seek to understand how splicing factor mutations in turn alter gene expression in MDS, and through this information, expand the molecular toolbox for investigating and treating the disease.

We have shown that a common, S34F mutation of the U2AF1 splicing factor subtly changes its binding site preference on gene transcripts. We have used this information to identify chemicals that alter the mutated splicing factors’ ability to bind and hence “splice” gene transcripts. We have leveraged single-molecule approaches to reveal that a recurrent splicing factor mutation alters the molecular gymnastics of its RNA complex.

Future studies remain needed to determine the mechanistic implications of our new single molecule finding, as well as to explore the potential of our U2AF-targeted chemical as a means to selectively kill MDS or cancer cells, while causing less harm to normal ones.

PUBLICATIONS

Okeyo-Owuor, T., B.S. White, R. Chatrikhi, D.R. Mohan, S. Kim, M. Griffith, L. Ding, S. Ketkar-Kulkarni, J. Hundal, K.M. Laird, C.L. Kielkopf, T.J. Ley, M.J. Walter, T.A. Graubert, U2AF1 mutations alter sequence specificity of pre-mRNA binding and splicing Leukemia, 2015 29(4): p. 909-17 doi: 10.1038/leu.2014.303

Fei, D.L., H. Motowski, R. Chatrikhi, S. Prasad, J. Yu, S. Gao, C.L. Kielkopf, R.K. Bradley, H. Varmus, Wild-Type U2AF1 Antagonizes the Splicing Program Characteristic of U2AF1-Mutant Tumors and Is Required for Cell Survival PLOS Genet 2016, 12(10): p. e1006384 doi: 10.1371/journal.pgen.1006384

Jenkins, J.L. and C.L. Kielkopf, Splicing Factor Mutations in Myelodysplasias: Insights from Spliceosome Structures Trends Genet, 2017, 33(5): p. 336-348 doi: 10.1016/j.tig.2017.03.001

Loerch, S. and C.L. Kielkopf, Unmasking the U2AF homology motif family: a bona fide protein-protein interaction motif in disguise RNA 2016, 22(12): p. 1795-1807 doi: 10.1261/rna.057950.116

Kielkopf, C.L., Insights from structures of cancer-relevant pre-mRNA splicing factors Curr. Opin. Gen., Dev., 2018, 48:57-66 doi: 10.1016/j.gde.2017.10.008

Glasser, E., A.A. Agrawal, J.L. Jenkins, and C.L. Kielkopf, Cancer-associated mutations mapped on high resolution structures of the U2AF2 RNA recognition motifs Biochemistry 2017, 56(36): p. 4757-4761 doi: 10.1021/acs.biochem.7b00551

  • ABOUT MDS
  • FUNDING MDS RESEARCH
  • EVANS MDS SUMMIT
  • LEADERSHIP
  • CONTACT
  • EDWARD P. EVANS FOUNDATION

Copyright © 2025 Evans MDS
Site Credits

  • ABOUT MDS
    • ABOUT MDS
    • RESOURCES
    • EDWARD P. EVANS
  • FUNDING MDS RESEARCH
    • FUNDING MDS RESEARCH
    • RESEARCHER PROFILES
    • FUNDING INFORMATION
    • CENTERS FOR MDS
  • EVANS MDS SUMMIT
  • LEADERSHIP
  • CONTACT
  • EDWARD P. EVANS FOUNDATION